Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adjudication
12%
Adverse Events
25%
Associated Complications
12%
Combination Vaccine
12%
Confirmed Cases
12%
Early Vaccination
12%
Efficacy Endpoint
25%
Endpoint Analysis
12%
Exclusion Criteria
12%
First Dose
12%
Follow-up Data
12%
Group Assignment
12%
Haemopoietic Stem Cell Transplantation
100%
Hazard Ratio
12%
Herpes Zoster
87%
Inactivated Vaccine
12%
Injection Site
12%
Laboratory Workers
12%
Medical Center
12%
Merck
12%
North America
12%
One Dose
25%
Opportunistic Infections
12%
Peri
12%
Phase II Trial
25%
Placebo
50%
Placebo Groups
87%
Placebo-controlled
12%
Randomized Double-blind
12%
Randomized Placebo-controlled Trial
100%
Relative Reduction
12%
Risk Difference
37%
Second Dose
12%
Serious Adverse Events
12%
South America
12%
South Asia
12%
South Europe
12%
Statistician
12%
Stem Cell Transplantation
12%
Success Criteria
25%
Transplant Center
12%
Transplantation
25%
Trial Participants
12%
Vaccine Effectiveness
25%
Varicella Vaccine
100%
Varicella Zoster Virus
12%
Varicella-zoster Virus Infection
12%
Whole-cell Vaccine
12%
Medicine and Dentistry
Inactivated Vaccine
7%
Inactivated Virus Vaccine
7%
Varicella Zoster Vaccine
100%
Varicella Zoster Virus
7%